Cargando…

High Burden of 30‐Day Readmissions After Acute Venous Thromboembolism in the United States

BACKGROUND: Venous thromboembolism (VTE) is the third leading cause of vascular disease and accounts for $10 billion in annual US healthcare costs. The nationwide burden of 30‐day readmissions after such events has not been comprehensively assessed. METHODS AND RESULTS: We analyzed adults ≥18 years...

Descripción completa

Detalles Bibliográficos
Autores principales: Secemsky, Eric A., Rosenfield, Kenneth, Kennedy, Kevin F., Jaff, Michael, Yeh, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064903/
https://www.ncbi.nlm.nih.gov/pubmed/29945913
http://dx.doi.org/10.1161/JAHA.118.009047
_version_ 1783342777705168896
author Secemsky, Eric A.
Rosenfield, Kenneth
Kennedy, Kevin F.
Jaff, Michael
Yeh, Robert W.
author_facet Secemsky, Eric A.
Rosenfield, Kenneth
Kennedy, Kevin F.
Jaff, Michael
Yeh, Robert W.
author_sort Secemsky, Eric A.
collection PubMed
description BACKGROUND: Venous thromboembolism (VTE) is the third leading cause of vascular disease and accounts for $10 billion in annual US healthcare costs. The nationwide burden of 30‐day readmissions after such events has not been comprehensively assessed. METHODS AND RESULTS: We analyzed adults ≥18 years of age with hospitalizations associated with acute VTE between January 1, 2010, and December 31, 2014, in the Nationwide Readmissions Database. International Classification of Disease, Ninth Revision, Clinical Modification (ICD‐9‐ CM) codes were used to identify hospitalizations associated with acute pulmonary embolism or deep vein thrombosis. The primary outcome was the rate of unplanned 30‐day readmission. Hierarchical logistic regression was used to calculate hospital‐specific 30‐day risk‐standardized readmission rates, a marker of healthcare quality. Among 1 176 335 hospitalizations with acute VTE, in‐hospital death occurred in 6.2%. VTE was associated with malignancy in 19.7%, recent surgery in 19.3%, recent trauma in 4.6%, hypercoagulability in 3.3%, and pregnancy in 1.0%. Among survivors to discharge, the 30‐day readmission rate was 17.5%, with no significant difference in rates across study years (17.4%–17.7%; P=0.10 for trend). Major predictors of readmission were malignancy (relative risk, 1.49, 95% confidence interval 1.47‐1.50), Medicaid insurance (relative risk, 1.48, 95% confidence interval 1.46‐1.50), and nonelective index admission (relative risk, 1.31, 95% confidence interval 1.29‐1.33). Top causes of readmission included sepsis (9.6%) and procedural complications (8.1%). Median rehospitalization costs were $9781.7 (interquartile range, $5430.7–$18 784.1), and 8.1% died during readmission. The interquartile range in risk‐standardized readmission rates was 16.6% to 18.3%, suggesting modest interhospital heterogeneity in readmission risk. CONCLUSIONS: Nearly 1 in 5 patients with acute VTE were readmitted within 30 days. Predictors and causes of readmission were primarily related to patient characteristics and complications from comorbid conditions, whereas healthcare quality had a moderate impact on readmission risk.
format Online
Article
Text
id pubmed-6064903
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60649032018-08-09 High Burden of 30‐Day Readmissions After Acute Venous Thromboembolism in the United States Secemsky, Eric A. Rosenfield, Kenneth Kennedy, Kevin F. Jaff, Michael Yeh, Robert W. J Am Heart Assoc Original Research BACKGROUND: Venous thromboembolism (VTE) is the third leading cause of vascular disease and accounts for $10 billion in annual US healthcare costs. The nationwide burden of 30‐day readmissions after such events has not been comprehensively assessed. METHODS AND RESULTS: We analyzed adults ≥18 years of age with hospitalizations associated with acute VTE between January 1, 2010, and December 31, 2014, in the Nationwide Readmissions Database. International Classification of Disease, Ninth Revision, Clinical Modification (ICD‐9‐ CM) codes were used to identify hospitalizations associated with acute pulmonary embolism or deep vein thrombosis. The primary outcome was the rate of unplanned 30‐day readmission. Hierarchical logistic regression was used to calculate hospital‐specific 30‐day risk‐standardized readmission rates, a marker of healthcare quality. Among 1 176 335 hospitalizations with acute VTE, in‐hospital death occurred in 6.2%. VTE was associated with malignancy in 19.7%, recent surgery in 19.3%, recent trauma in 4.6%, hypercoagulability in 3.3%, and pregnancy in 1.0%. Among survivors to discharge, the 30‐day readmission rate was 17.5%, with no significant difference in rates across study years (17.4%–17.7%; P=0.10 for trend). Major predictors of readmission were malignancy (relative risk, 1.49, 95% confidence interval 1.47‐1.50), Medicaid insurance (relative risk, 1.48, 95% confidence interval 1.46‐1.50), and nonelective index admission (relative risk, 1.31, 95% confidence interval 1.29‐1.33). Top causes of readmission included sepsis (9.6%) and procedural complications (8.1%). Median rehospitalization costs were $9781.7 (interquartile range, $5430.7–$18 784.1), and 8.1% died during readmission. The interquartile range in risk‐standardized readmission rates was 16.6% to 18.3%, suggesting modest interhospital heterogeneity in readmission risk. CONCLUSIONS: Nearly 1 in 5 patients with acute VTE were readmitted within 30 days. Predictors and causes of readmission were primarily related to patient characteristics and complications from comorbid conditions, whereas healthcare quality had a moderate impact on readmission risk. John Wiley and Sons Inc. 2018-06-26 /pmc/articles/PMC6064903/ /pubmed/29945913 http://dx.doi.org/10.1161/JAHA.118.009047 Text en © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Secemsky, Eric A.
Rosenfield, Kenneth
Kennedy, Kevin F.
Jaff, Michael
Yeh, Robert W.
High Burden of 30‐Day Readmissions After Acute Venous Thromboembolism in the United States
title High Burden of 30‐Day Readmissions After Acute Venous Thromboembolism in the United States
title_full High Burden of 30‐Day Readmissions After Acute Venous Thromboembolism in the United States
title_fullStr High Burden of 30‐Day Readmissions After Acute Venous Thromboembolism in the United States
title_full_unstemmed High Burden of 30‐Day Readmissions After Acute Venous Thromboembolism in the United States
title_short High Burden of 30‐Day Readmissions After Acute Venous Thromboembolism in the United States
title_sort high burden of 30‐day readmissions after acute venous thromboembolism in the united states
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064903/
https://www.ncbi.nlm.nih.gov/pubmed/29945913
http://dx.doi.org/10.1161/JAHA.118.009047
work_keys_str_mv AT secemskyerica highburdenof30dayreadmissionsafteracutevenousthromboembolismintheunitedstates
AT rosenfieldkenneth highburdenof30dayreadmissionsafteracutevenousthromboembolismintheunitedstates
AT kennedykevinf highburdenof30dayreadmissionsafteracutevenousthromboembolismintheunitedstates
AT jaffmichael highburdenof30dayreadmissionsafteracutevenousthromboembolismintheunitedstates
AT yehrobertw highburdenof30dayreadmissionsafteracutevenousthromboembolismintheunitedstates